| Total | HLA-DQ 2.5/8/2.2-positive, observed,(expected) n | HLA-DQ 2.5/8/2.2-positive, RR (95% CI) | Excess HLA-DQ 2.5/8/2.2-positive, n | Prevalence per 1.000 (95% CI) |
---|---|---|---|---|---|
Biopsy-confirmed CD | |||||
 F + M | 356 | 351 | 1.78 (1.71 to 1.84)a |  | NA |
Biopsy-confirmed CD; four of five HLA-DQ2.5-DQ8-DQ2.2- re-investigated | |||||
 F + M | 352 | 351 | 1.80 (1.73 to 1.89)a |  | NA |
Community random sample of age-stratified cohorts of adults | |||||
 F | 1,065 | 596 | 1 |  | 0 |
 M | 921 | 513 | 1 |  | 0 |
Community sample: initially positive for TG2 IgA | |||||
 F | 48 | 34 (27) | 1.28 (1.06 to 1.55)b | 14 | 13.4 (2.4 to 26.8) |
 M | 68 | 44 (38) | 1.18 (0.98 to 1.42)NS | 12 | 13.2 (−2.9 to 32.8) |
Community sample: initially positive for TG2 IgA, and confirmed positive for EMA | |||||
 F | 13 | 13 (7) | 1.80 (1.71 to 1.90)c | 11 | 10.8 (9.5 to 12.1) |
 M | 13 | 13 (7) | 1.82 (1.71 to 1.93)c | 12 | 12.5 (10.9 to 14.2) |
Community sample: initially positive for composite TG2/DGP IgA/IgG | |||||
 F | 55 | 41 (31) | 1.36 (1.15 to 1.60)d | 20 | 19.2 (7.5 to 32.9) |
 M | 73 | 46 (41) | 1.14 (0.95 to 1.38) NS | 11 | 11.6 (−5.4 to 32.0) |
Community sample: initially positive for composite TG2/DGP IgA/IgG, and confirmed positive for TG2 IgA, DGP-G-+, or DGP-A | |||||
 F | 37 | 30 (21) | 1.47 (1.23 to 1.74)e | 19 | 17.5 (8.9 to 27.6) |
 M | 44 | 29 (25) | 1.19 (0.96 to 1.49) NS | 9 | 9.8 (−2.7 to 25.3) |
Community sample: – initially positive for TG2/DGP IgA/IgG, and confirmed positive for TG2 IgA, DGP-G, and DGP-A | |||||
 F | 10 | 10 (6) | 1.80 (1.71 to 1.90)d | 9 | 8.3 (7.3 to 9.3) |
 M | 11 | 11 (6) | 1.82 (1.72 to 1.93)e | 10 | 10.6 (9.3 to 12.1) |